Tocilizumab for Patients With Giant Cell Arteritis

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

December 31, 2014

Study Completion Date

September 30, 2015

Conditions
Giant Cell Arteritis
Interventions
DRUG

Tocilizumab + Glucocorticoids (GCs)

Tocilizumab 8mg/kg every 4 weeks until week 52.

DRUG

Placebo + Glucocorticoids (GCs)

Placebo every 4 weeks until week 52.

Trial Locations (1)

3010

Department of Rheumatology, Clinical Immunology Allergology, University Hospital, Inselspital, Bern

All Listed Sponsors
collaborator

University of Bern

OTHER

collaborator

Roche Pharma AG

INDUSTRY

lead

Insel Gruppe AG, University Hospital Bern

OTHER

NCT01450137 - Tocilizumab for Patients With Giant Cell Arteritis | Biotech Hunter | Biotech Hunter